Orthopaedic Department, West China Hospital, Sichuan University, Chengdu (610041), PR China.
Joint Bone Spine. 2012 Jan;79(1):67-72. doi: 10.1016/j.jbspin.2011.02.020. Epub 2011 Jul 13.
The treatment of osteonecrosis of the femoral head (ONFH) remains controversial. A recently proposed treatment is multiple drilling core decompression combined with systemic alendronate as a femoral head-preserving procedure for ONFH. However, it is not known whether alendronate enhances the risk of collapse. We wondered whether the combined procedure could delay or prevent progression of ONFH compared to multiple drilling alone.
Patients with early-stage ONFH were randomly assigned to be treated with either multiple drilling combined with alendronate (47 patients, 67 hips) or multiple drilling alone (46 patients, 60 hips). We defined failure as the need for THA or a Harris score less than 70. The minimum follow-up was 48 months for the 77 patients completing the protocol.
After a minimum 4-year follow-up, 91% (40/44) of patients with Stage II disease and 62% (8/13) of patients with Stage III disease had not required THA in alendronate group, compared to 79% (31/39) of patients with Stage II disease and 46% (6/13) of patients with Stage III disease had not required THA in control group (P=0.12, P=0.047, respectively). Small or medium and central lesions had a better successful rate in both groups. Risk factors did not seem to affect the clinical successful rate of this procedure.
Multiple small-diameter drilling core decompression combined with systemic alendronate administration can reduce pain and delay progression of early-stage ONFH. Even in Ficat IIA and III hips, some benefit was obtained from this approach at least delay in the need for THA.
股骨头坏死(ONFH)的治疗仍存在争议。最近提出的一种治疗方法是多次钻孔核心减压联合全身阿伦膦酸盐作为保头治疗ONFH 的方法。然而,尚不清楚阿伦膦酸盐是否会增加塌陷的风险。我们想知道与单纯多次钻孔相比,联合治疗是否能延缓或预防 ONFH 的进展。
将早期 ONFH 患者随机分为接受多次钻孔联合阿伦膦酸盐治疗(47 例,67 髋)或单纯多次钻孔治疗(46 例,60 髋)。我们将失败定义为需要进行全髋关节置换术或 Harris 评分低于 70 分。77 例完成方案的患者的最低随访时间为 48 个月。
经过至少 4 年的随访,Ⅱ期疾病患者中有 91%(40/44)和Ⅲ期疾病患者中有 62%(8/13)不需要接受阿伦膦酸盐治疗,而对照组中Ⅱ期疾病患者中有 79%(31/39)和Ⅲ期疾病患者中有 46%(6/13)不需要接受 THA(P=0.12,P=0.047)。小或中等和中央病变在两组中都有更好的成功率。危险因素似乎不会影响该手术的临床成功率。
多次小直径钻孔核心减压联合全身阿伦膦酸盐给药可减轻疼痛并延缓早期 ONFH 的进展。即使在 Ficat IIA 和 III 期髋关节中,该方法至少在需要进行 THA 方面也能获得一定的益处。